Search hospitals > Michigan > Ann Arbor

University of Michigan

Claim this profile
Ann Arbor, Michigan 48109
Global Leader in Cancer
Global Leader in Fibrosis
Conducts research for Lymphoma
Conducts research for Breast Cancer
Conducts research for Syndrome
1923 reported clinical trials
263 medical researchers
Photo of University of Michigan in Ann ArborPhoto of University of Michigan in Ann Arbor

Summary

University of Michigan is a medical facility located in Ann Arbor, Michigan. This center is recognized for care of Cancer, Fibrosis, Lymphoma, Breast Cancer, Syndrome and other specialties. University of Michigan is involved with conducting 1,923 clinical trials across 1,848 conditions. There are 263 research doctors associated with this hospital, such as Rajen Mody, MD, MS, Elie G. Dib, Paul Swiecicki, and Rashmi Chugh, MD.

Area of expertise

1Cancer
Global Leader
University of Michigan has run 113 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
RET
2Fibrosis
Global Leader
University of Michigan has run 90 trials for Fibrosis. Some of their research focus areas include:
CFTR
rs3570920 TT positive
6MWD

Top PIs

Clinical Trials running at University of Michigan

Breast Cancer
Coronavirus
Ulcerative Colitis
Lymphoma
Multiple Myeloma
COVID-19
Liver Cirrhosis
Syndrome
Cystic Fibrosis
Heart Failure
Image of trial facility.

Sacituzumab Govitecan

for Triple-Negative Breast Cancer

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumors do express PD-L1.
Recruiting4 awards Phase 3
Image of trial facility.

Sacituzumab Govitecan + Pembrolizumab

for Triple-Negative Breast Cancer

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
Recruiting4 awards Phase 3
Image of trial facility.

Tucatinib Combination

for Breast Cancer

Patients with advanced HER2+ breast cancer on maintenance trastuzumab/pertuzumab or T-DM1 with 1st or 2nd intracranial disease event (brain metastases) and stable extracranial disease will be enrolled. They will receive local therapy with stereotactic radiosurgery ± surgical resection if indicated followed by enrollment. Patients will continue standard of care trastuzumab/pertuzumab or T-DM1 with the addition of tucatinib. Hormone receptor positive patients requiring endocrine therapy should continue. Study treatment will continue until disease progression or intolerable side effects. Patients on trial with extracranial disease progression with stable intracranial disease should continue tucatinib into next line of therapy.
Recruiting3 awards Phase 29 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of Michigan?
University of Michigan is a medical facility located in Ann Arbor, Michigan. This center is recognized for care of Cancer, Fibrosis, Lymphoma, Breast Cancer, Syndrome and other specialties. University of Michigan is involved with conducting 1,923 clinical trials across 1,848 conditions. There are 263 research doctors associated with this hospital, such as Rajen Mody, MD, MS, Elie G. Dib, Paul Swiecicki, and Rashmi Chugh, MD.
Where is University of Michigan located?
To reach the University of Michigan Hospital in Ann Arbor, Michigan from the North, use I-275 South to M-14 West, then US-23 South, exiting at Geddes Road (exit 39). Turn left onto Center Drive to the Patient/Visitor Parking Deck. From the West, take I-94, exit at "Ann Arbor" (Exit 172), follow Jackson Rd (becomes Huron) for 2.5 miles, turn left onto Glen, then right onto East Medical Center Drive to park in P2.
Who should I call to ask about financial aid or insurance network?
**University of Michigan Hospital - Financial Assistance and Insurance Inquiries** - **Patient Financial Experience**: For billing and insurance queries, contact 855-855-0863 or 734-615-0863, Monday – Friday, 8 a.m. – 4 p.m. - **Patient Financial Counselors**: For financial assistance, including the Financial Assistance Program, MSupport, reach out at 877-326-9155 (8 a.m. - 4 p.m., Monday-Friday) or email [mailto:[email protected]](mailto:[email protected]). - **Health Information Management Department**: For information about MyUofMHealth, call 734-615-0872 (Monday - Friday 7 a.m. – 7 p.m., Saturday 8 a.m. – 1 p.m.). - For specific concerns, contact the Patient Billing Office at 734-764-7380 or [mailto:uhs-busbill@med.umich.edu](mailto:uhs-busbill@med.umich.edu).
What insurance does University of Michigan accept?
The University of Michigan accepts a wide range of insurance plans, including but not limited to Medicare Advantage Plans, Community Blue PPO, Comprehensive Major Medical, and GradCare. Michigan Medicine is also in-network with numerous health insurance plans such as AARP (UnitedHealthcare) Medicare, Affordable Choices (SRC) Indemnity and PPO, and many UnitedHealthcare plans including Choice, Choice Plus, and Medicare Advantage PPO. For behavioral health benefits, it's advised to verify participation status with your insurance provider prior to scheduling services.
What awards or recognition has University of Michigan received?
The University of Michigan Hospital in Ann Arbor, Michigan, is renowned for its exceptional research and care, receiving numerous awards and funding opportunities. Notably, the Biosciences Initiative awarded five scientists for their groundbreaking biological sciences research. Additionally, the hospital offers various research recognition awards for faculty and staff, including the Research Faculty Recognition Award, which grants a $1,500 award for outstanding scholarly achievements, and eleven awards for research staff excellence.